Pfizer Inc. (NYSE: PFE) reported its third quarter 2025 earnings results today. Revenues were $16.7 billion, down 6% on a reported basis and 7% on an operational basis year-over-year. Net income decreased 21% to $3.5 billion, or $0.62 per share, compared to last year. Adjusted EPS declined 18% to $0.87. Revenue and earnings beat expectations. […]
“Pfizer Inc. (NYSE: PFE) reported its third quarter 2025 earnings results today. Revenues were $16.7 billion, down 6% on a reported basis and 7% on an operational basis year-over-year. Net income decreased 21% to $3.5 billion, or $0.62 per share, compared to last year. Adjusted EPS declined 18% to $0.87. Revenue and earnings beat expectations. […]
· November 4, 2025
Pfizer Inc. (NYSE: PFE) reported its third quarter 2025 earnings results today.
Revenues were $16.7 billion, down 6% on a reported basis and 7% on an operational basis year-over-year.
Net income decreased 21% to $3.5 billion, or $0.62 per share, compared to last year. Adjusted EPS declined 18% to $0.87.
Revenue and earnings beat expectations.
For the full year of 2025, Pfizer expects revenue of $61-64 billion. Adjusted EPS is now expected to be $3.00-3.15.
The stock stayed red during premarket hours on Tuesday.
